Life Science Investing Instil Bio Announces ImmuneOnco's Presentation of '2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer
Life Science Investing Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
